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Background: Increased pulmonary arterial vascular smooth muscle (PAVSM) cell proliferation is a key
pathophysiological component of pulmonary vascular remodeling in pulmonary arterial hypertension (PH). The
long-acting β2-adrenergic receptor (β2AR) agonist formoterol, a racemate comprised of (R,R)- and (S,S)-enantiomers,
is commonly used as a vasodilator in chronic obstructive pulmonary disease (COPD). PH, a common complication
of COPD, increases patients’ morbidity and reduces survival. Recent studies demonstrate that formoterol has
anti-proliferative effects on airway smooth muscle cells and bronchial fibroblasts. The effects of formoterol and its
enantiomers on PAVSM cell proliferation are not determined. The goals of this study were to examine effects of
racemic formoterol and its enantiomers on PAVSM cell proliferation as it relates to COPD-associated PH.
Methods: Basal, thrombin-, PDGF- and chronic hypoxia-induced proliferation of primary human PAVSM cells was
examined by DNA synthesis analysis using BrdU incorporation assay. ERK1/2, mTORC1 and mTORC2 activation were
determined by phosphorylation levels of ERK1/2, ribosomal protein S6 and S473-Akt using immunoblot analysis.
Results: We found that (R,R) and racemic formoterol inhibited basal, thrombin- and chronic hypoxia-induced
proliferation of human PAVSM cells while (S,S) formoterol had lesser inhibitory effect. The β2AR blocker propranolol
abrogated the growth inhibitory effect of formoterol. (R,R), but not (S,S) formoterol attenuated basal, thrombin- and
chronic hypoxia-induced ERK1/2 phosphorylation, but had little effect on Akt and S6 phosphorylation levels.
Formoterol and its enantiomers did not significantly affect PDGF-induced DNA synthesis and PDGF-dependent
ERK1/2, S473-Akt and S6 phosphorylation in human PAVSM cells.
Conclusions: Formoterol inhibits basal, thrombin-, and chronic hypoxia-, but not PDGF-induced human PAVSM cell
proliferation and ERK1/2, but has little effect on mTORC1 and mTORC2 signaling. Anti-proliferative effects of
formoterol depend predominantly on its (R,R) enantiomer and require the binding with β2AR. These data suggest
that (R,R) formoterol may be considered as potential adjuvant therapy to inhibit PAVSM cell proliferation in
COPD-associated PH.
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Pulmonary arterial vascular smooth muscle (PAVSM)
cell proliferation is one of the key pathophysiological
components of vascular remodeling in pulmonary hyper-
tension (PH) [1,2]. PH is a common complication of
chronic obstructive pulmonary disease (COPD), which
is strongly associated with decreased quality of life,
increased morbidity and reduced survival of COPD
patients [3,4]. The major pathological manifestations of
PH are vasoconstriction and remodeling of small muscu-
lar pulmonary arteries (PA). Prolonged exposure to hyp-
oxia, growth factors and pro-inflammatory cytokines
induces PAVSM proliferation and pulmonary vascular
remodeling leading to persistent elevation of pulmonary
vascular resistance, right ventricular failure and death
[2,5,6]. Systemic vasodilators, however, have not been
found to be effective therapy for COPD-associated PH
[6] and therapeutic options to target pulmonary vascular
remodeling are needed.
β2 adrenoreceptor (AR), a member of the G-protein
coupled receptor family, is the major subtype of βAR in
SM cells. Binding with β2AR agonists induces β2AR
coupling with Gs proteins, activation of adenylate cyclase
and increase of cellular cAMP levels leading to parallel
activation of protein kinase A (PKA) and Epac1 that
synergize in mediating cAMP-dependent growth inhib-
ition of VSM cells [7-11] suggesting that β2AR agonists
may be considered as an attractive therapeutic approach
to inhibit PAVSM cell proliferation in PH.
Formoterol is a long-acting β2AR agonist that is com-
monly used as a bronchodilator to treat patients with
COPD [12,13]. Formoterol is available in two formula-
tions: racemic formoterol that consists of equal amounts
of (R,R) and (S,S) enantiomers, and purified (R,R) for-
moterol. (R,R) formoterol has 1000-times greater affinity
to β2AR than (S,S) enantiomer and shows improved
bronchodilator effects compared to formoterol racemate
[8]. Recent data demonstrate that, in addition to its
function as a bronchodilator, racemic formoterol also
acts as an anti-proliferative agent for airway smooth
muscle cells [9] and human bronchial fibroblasts [14].
Currently, no information is available about the effects
of formoterol in PAVSM cell proliferation as it relates to
COPD-associated PH, and comparative effects of ra-
cemic formoterol vs. its (R,R) and (S,S) enantiomers on
PAVSM cell proliferation are also not examined.
The mechanisms by which formoterol regulates cell pro-
liferation are not well understood. cAMP uptake regulates
Raf1-extracellular signal-regulated kinases 1/2 (ERK1/2)
cascade via PKA-specific direct phosphorylation of Raf1
or PKA- and Epac1-dependent Rap1 regulation [7,15-18].
cAMP is also shown to down-regulate protein tyrosine
phosphorylation in VSM cells [19]. Studies from our
laboratory and others demonstrate that ERK1/2 andmammalian target of rapamycin (mTOR), downstream
effectors of receptor tyrosine kinases (RTK), are two major
positive regulators of PAVSM cell proliferation induced by
mitogens and chronic hypoxia [20-25]. ERK1/2 is required
for PDGF-, insulin- and thrombin-induced proliferation of
aortic and pulmonary arterial VSM cells [22,23]; and
pharmacological inhibition of MEK-ERK1/2 signaling
abolishes chronic hypoxia-induced rat PAVSM cell prolif-
eration [24]. mTOR forms two functionally distinct com-
plexes, mTORC1 and mTORC2 [25,26]. Chronic hypoxia,
PDGF, and thrombin activate mTORC1 in PAVSM and
endothelial cells that, in turn, stimulates cell growth via
regulation of S6 kinase 1 (S6K1) and 4 EB-P1 [20-25]. The
mTORC1 inhibitor rapamycin attenuates pulmonary vas-
cular remodeling in experimental PH [27,28] and demon-
strated benefits in treatment of patients with PH [29].
mTORC2 activates serine-threonine kinase Akt via spe-
cific phosphorylation at S-473 [30]. We recently reported
that chronic hypoxia and PDGF activate mTORC2 signal-
ing that is required for proliferation of human and rat
PAVSM cells [25]. The effects of formoterol and its enan-
tiomers on ERK1/2 and mTOR signaling pathways in
PAVSM cells, however, remain to be elucidated.
The goal of this study was to evaluate the effects of ra-
cemic formoterol and its (R,R) and (S,S) enantiomers on
proliferation of human PAVSM cells induced by PDGF,
thrombin, and chronic hypoxia, recognized triggers of
PAVSM cell proliferation and vascular remodeling in
COPD-associated PH [31]. We found that formoterol
inhibits basal, thrombin-, and chronic hypoxia-, but not
PDGF-induced proliferation of human PAVSM cells and
ERK1/2 phosphorylation while having little effect on
mTOR signaling. We also show that the anti-proliferative
effects of formoterol require its binding with β2AR and
that (R,R) formoterol shows improved anti-proliferative
effects compared to racemic formoterol. Taken together,
our data demonstrate that formoterol inhibits human
PAVSM cell proliferation caused by certain PH-related
stimuli and suggest that (R,R) formoterol may be consid-
ered as a potential adjuvant therapy to attenuate PAVSM
cell proliferation in COPD-associated PH.
Methods
Cell culture
Human PAVSM cells were dissociated from pulmonary
arteries from failed donor lungs that were obtained
from the National Disease Research Interchange (NDRI)
(Philadelphia, PA), in accordance with procedures approved
by the University of Pennsylvania Committee on Studies
Involving Human Beings as previously described [20,25].
Briefly, a segment of human pulmonary artery just prox-
imal to the lung entry was removed under aseptic condi-
tions, cleaned from connective and fat tissues and dissected
as follows: the media of pulmonary artery was dissected
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atic digestion in 10 ml of buffer containing 0.2 mM CaCl2,
640 U/ml collagenase, 1 mg/ml soybean trypsin inhibitor
and 10 U/ml elastase for approximately 60 min in a shaking
water bath at 37°C. The cell suspension was filtered
through 105 μm Nytex mesh, and the filtrate was
washed with equal volumes of cold Ham's F-12 medium
(Life Technologies, Grand Island, NY) supplemented
with 10% FBS (HyClone, Logan, UT). Cells were plated
on tissue culture plates covered with Vitrogen (Cohesion
Technologies Inc., Palo Alto, CA). Cells were cultured in
Ham's F-12 media supplemented with 10% FBS (Becton
Dickinson, Bedford, MA), 100 U/ml penicillin, and
0.1 mg/ml streptomycin.
For chronic hypoxia experiments, cells were main-
tained either in normoxic (21% O2, 5% CO2) or in hyp-
oxic (1% O2, 5% CO2) conditions for 7 days in complete
media and then for 48 h in serum-free media supple-
mented with 0.1% BSA. 1% O2 was used as we described
[25] to reproduce the tissue oxygen levels of moderate
chronic hypoxia [32,33] based on data obtained from
the rat chronic hypoxia model of PH [34,35]. To avoid
re-oxygenation, fresh complete or serum-free media
was pre-equilibrated at 1% O2, before adding to PAVSM
cells grown under hypoxia. Primary human PAVSM
cells in subculture during the second through tenth cell
passages were used. All experiments were performed
using a minimum of three different cell cultures. Each
human PAVSM cell culture was established using pul-
monary arterial tissue from a single human donor.
DNA synthesis analysis
Cells grown under normoxia or chronic hypoxia were
serum deprived for 48 h, treated with 0.1, 1, or 10 ng/ml
PDGF-BB, 1 U/ml thrombin, 0.2, 2, or 20 μM racemic,
(R,R), or (S,S) formoterol, or diluent for 18 h followed
by DNA synthesis analysis using the BrdU incorporation
assays as we described [25,36-38]. Briefly, cells were
incubated with 10 μM BrdU for 24 h, fixed with 3.7%
paraformaldehyde (Polysciences, Inc., Warrington, PA)
for 15 min and permeabilized with 0.1% Triton X-100
for 30 min at room temperature. Following denaturation
of DNA with 4 N HCl (3 min at room temperature),
incubated for 1 h at 37oC with 2 μg/ml murine anti-
BrdU primary (Becton Dickinson, San Jose, CA) and
10 μg/ml Texas Red-conjugated anti-mouse secondary
(Jackson ImmunoResearch Laboratories, West Grove,
PA) antibodies for 1 h at 37°C to detect BrdU-positive
cells. To detect the total number of nuclei, cells were
incubated with 1 μg/ml DAPI. Then, cells were visua-
lized using Eclipse Nikon TE2000E fluorescent micro-
scope (200x magnification), and automatic counts of
BrdU-positive and total number of cells were performed
using Image-Pro Plus 5.1 software.Immunoblot analysis
Whole cell lysates were prepared using a buffer com-
prised of 40 mM HEPES (pH 7.5), 120 mM NaCl, 1 mM
EDTA, 10 mM sodium pyrophosphate (Na4P2O7 x
10H2O), 10 mM β-glycerophosphate, 50 mM NaF,
1.5 mM Na3VO4, 1% Triton X-100, EDTA-free inhibitor
cocktail. Protein contents were measured using a Bio-
Rad protein assay reagent kit. Equal amounts of lysate,
adjusted for protein content, were subjected to SDS-PAGE
and then immunoblot analysis. The blots were exposed to
anti-phospho-S6 ribosomal protein, anti-total S6, anti-
phospho Akt Ser-473, anti-total Akt, anti-phospho ERK,
anti-total ERK, anti-phospho S6K1 T-389, and anti-total
S6K1 antibodies (Cell Signaling Technology, Inc., Beverly,
MA). All antibodies were in 20 mM Tris (pH 7.5),
150 mM NaCl (TBS) plus 0.5% Tween 20 (TBST), and all
incubations were for overnight at 4°C. After 3 washes in
TBST, the nitrocellulose membranes were exposed to
horseradish peroxidase-conjugated secondary antibody
(Boehringer-Mannheim, Indianapolis, IN), washed five
times in TBST and visualized using enhanced chemilumin-
escence (ECL) (Amersham, Arlington Heights, IL).
Data analysis
Data points from each condition are represented as the
mean values ± SE. Three independent repetitions were
performed for each experimental condition. Statistical
analysis was performed using StatView software. Statisti-
cally significant differences among groups were assessed
with the analysis of variance (ANOVA) (Bonferroni-Dunn)
with values of p < 0.05 sufficient to reject the null hypoth-
esis for all analyses. All experiments were designed with
matched control conditions within each experiment to
enable statistical comparison as paired samples.
Results
Formoterol inhibits basal and thrombin-, but not
PDGF-induced human PAVSM cell proliferation
Because formoterol inhibits proliferation of human bron-
chus fibroblasts and airway smooth muscle cells [9,14], we
examined the effects of formoterol and its enantiomers on
the proliferation of human PAVSM cells under serum-
depleted conditions and in the presence of thrombin and
PDGF, confirmed PAVSM mitogens that are involved in
PH pathogenesis [20,39,40]. Consistent with our published
data [20], serum-deprived PAVSM cells had modest levels
of DNA synthesis that were significantly increased by treat-
ment with PDGF and thrombin (Figure 1A). Racemic
formoterol inhibited DNA synthesis in serum-deprived
human PAVSM cells in a concentration-dependent manner
(Figure 1B). (R,R) formoterol had a greater inhibitory effect
on human PAVSM cell proliferation compared to racemic
formoterol (IC50 ~ 1 μM and ~ 4 μM, respectively). (S,S)-
formoterol had modest inhibitory effect (IC50 ~ 20 μM)
A B
C D
Figure 1 Formoterol inhibits basal and thrombin-, but not PDGF-induced DNA synthesis in human PAVSM cells. A: Cells serum-deprived
for 48 h were treated for 18 h with 1 U/ml thrombin, 10 ng/ml PDGF, or diluent followed by DNA synthesis analysis using the BrdU incorporation
assay. Data represent a percentage of BrdU-positive cells per total number of cells taken as 100%. Data are mean values ± SE from three
independent experiments. A minimum of 200 cells per each condition were analyzed in each experiment. B-D: Cells serum-deprived for 48 h
were treated with 0.2, 2, 20 μM (R,R)-, (S,S)-, racemic formoterol, or diluent in the presence of vehicle (B), 1 U/ml thrombin (C) or 10 ng/ml PDGF
(D) followed by DNA synthesis analysis using the BrdU incorporation assay. Data are means ± SE from three separate experiments, n = 3 for each
experimental condition. *p < 0.001 for formoterol vs. diluent and for thrombin + (R,R) formoterol vs. thrombin by ANOVA (Bonferroni-Dunn). A
minimum of 200 cells per condition were analyzed in each experiment.
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dose. (R,R) and, to a lesser extent, racemic formoterol
significantly inhibited thrombin-induced human PAVSM
cell proliferation (IC50 for (R,R) formoterol ~ 20 μM), and
(S,S) formoterol had no significant effect (Figure 1C). Both
racemic and (S,S) formoterol did not provide 50% inhib-
ition of cell proliferation even when administrated in high
doses (20 μM). Interestingly, racemic formoterol and both
formoterol enantiomers had no effect on PDGF-induced
proliferation of human PAVSM cells (Figure 1D). These
data demonstrate that formoterol inhibits basal and throm-
bin-induced, but not PDGF-stimulated human PAVSM cell
proliferation and suggest that growth inhibitory effects of
formoterol depend predominantly on its (R,R), but not
(S,S) enantiomer.
Formoterol inhibits PAVSM cell proliferation caused by
chronic hypoxia exposure
Because chronic hypoxia is one of the confirmed triggers
of PAVSM cell proliferation and pulmonary vascular
remodeling in PH [2,41], we next examined whetherformoterol modulates chronic hypoxia-induced PAVSM
cell proliferation. As we demonstrated previously [25],
chronic hypoxia increased basal and PDGF-induced
human PAVSM cell proliferation compared to normoxia-
maintained cells (Figure 2A and B, respectively). Impor-
tantly, (R,R)-formoterol inhibited chronic hypoxia-induced
PAVSM cell proliferation by the level comparable to
normoxia-maintained cells, racemic formoterol had lesser
inhibitory effect, and no significant differences in cell pro-
liferation were observed in (S,S) formoterol- vs. diluent-
treated PAVSMC under chronic hypoxia (Figure 2A).
Interestingly, 10 μM (R,R) and racemic formoterol attenu-
ated PAVSM cell proliferation in the presence of 0.1 ng/ml
PDGF, but had little effect on the proliferation induced by
higher PDGF doses (1 and 10 ng/ml) either under chronic
hypoxia or normoxia (Figure 2B) demonstrating that
PDGF-induced PAVSM cell proliferation is not susceptible
to formoterol. Taken together, these data demonstrate that
formoterol attenuates basal, but not PDGF-induced human
PAVSM proliferation under chronic hypoxia and that for-
moterol acts predominantly through its (R,R) enantiomer.
BA
Figure 2 Formoterol inhibits chronic hypoxia-induced human PAVSM cell proliferation. Cells grown under chronic hypoxia (1% O2) or
normoxia (21% O2) for 7 days were serum-deprived for 48 h, treated with 10 μM (R,R)-, (S,S)-, racemic formoterol, or diluent (A), or 0.1, 1, 10 ng/ml
PDGF, or diluent in the absence or presence of 10 μM (R,R) and racemic formoterol (B), and then DNA synthesis analysis using the BrdU
incorporation assay was performed. DNA synthesis was measured as a percentage of the BrdU-positive cells per total number of cells. Data are
means ± SE by ANOVA (Bonferroni-Dunn) from three independent experiments; n = 3 for each experimental condition. A minimum of 200 cells
per condition were analyzed in each experiment. A: *p < 0.01 for diluent-treated cells under normoxia vs. hypoxia and for racemic formoterol vs.
(R,R) formoterol under normoxia; **p < 0.001 for racemic formoterol vs. (R,R) formoterol under hypoxia. B: *p < 0.001 for hypoxia vs. normoxia;
**p < 0.01 for diluent vs. (R,R) formoterol under normoxia; for diluent vs. racemic formoterol under hypoxia; and for 0.1 ng/ml PDGF vs. 0.1 ng/ml
PDGF + racemic formoterol under hypoxia; ***p < 0.001 for 0.1 ng/ml PDGF vs. 0.1 ng/ml PDGF + (R,R) formoterol under normoxia; for diluent vs.
(R,R) formoterol under hypoxia; and for 0.1 ng/ml PDGF + (R,R) formoterol under hypoxia.
Goncharova et al. Respiratory Research 2012, 13:109 Page 5 of 12
http://respiratory-research.com/content/13/1/109Binding with β2AR is required for formoterol-induced
inhibition of human PAVSM cell proliferation
Since the bronchodilatory functions of formoterol require
binding of its (R,R) enantiomer with specific β2AR [42],
we next examined whether binding with β2AR contributes
to anti-proliferative effects of formoterol in human
PAVSM cells. Serum-deprived cells were treated with the
β2AR blocker propranolol in the presence of 0.2-20 μM of
(R,R), (S,S) and racemic formoterol, or diluent and then
subjected to DNA synthesis analysis using the BrdU in-
corporation assay. As seen in Figure 3 (grey bars), (R,R),
racemic, and, to a lesser extent, (S,S)-formoterol inhibited
DNA synthesis in human PAVSM cells depending on
agent concentration. Importantly, propranolol completely
reversed inhibitory effects of racemic, (R,R)-, and (S,S)-
formoterol on PAVSM cell proliferation (Figure 3, black
bars). These data demonstrate that binding with β2AR is
required for formoterol-dependent inhibition of human
PAVSM cell proliferation.(R,R) formoterol inhibits basal and thrombin-, but not PDGF-
induced ERK1/2 phosphorylation in human PAVSM cells
Because ERK1/2 signaling is involved in human PAVSM
cell proliferation, we next determined the effects of formo-
terol and its enantiomers on ERK1/2 activatory phosphor-
ylation. As seen in Figure 4A, (R,R) and, to a lesser extent,
racemic, but not (S,S) formoterol inhibited basal ERK1/2
phosphorylation. Because PDGF and thrombin, but not
chronic hypoxia, markedly activate ERK1/2 in PAVSM
cells [20,25,43,44] (Figure 4B), ERK1/2 activation and
since (R,R) formoterol demonstrated maximal inhibitory
effects on human PAVSM cell proliferation and basal
ERK1/2 phosphorylation compared to racemic and (S,S)
formoterol, we next evaluated effects of (R,R) formoterol
on ERK1/2 phosphorylation induced by PDGF and throm-
bin. As seen in Figure 4C, D, (R,R) formoterol abrogated
thrombin-induced ERK1/2 phosphorylation while having
little effect on ERK1/2 phosphorylation induced by PDGF
over a range of concentrations (0.1 - 10 ng/ml). Similarly,
Figure 3 β2AR blocker propranolol abolishes formoterol-induced inhibition of DNA synthesis in human PAVSM cells. Cells were
serum-deprived for 48 h, treated with 0.2, 2, 20 mM (R,R), (S,S), racemic formoterol, or diluent for 18 h in the presence (black bars) or absence
(grey bars) of 10 μM propranolol followed by DNA synthesis analysis using the BrdU incorporation assay. Data represent mean values ± SE from two
independent experiments, three repetitions per each experiment. *p < 0.001 for formoterol vs. formoterol + propranolol by ANOVA (Bonferroni-Dunn).
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induced ERK1/2 phosphorylation either under normoxia
or chronic hypoxia conditions (data not shown). Taken to-
gether, these data demonstrate that racemic and (R,R) for-
moterol down-regulate basal and thrombin-induced, but
not PDGF-dependent ERK1/2 phosphorylation in human
PAVSM cells.
Formoterol has no effect on mTOR signaling in human
PAVSM cells
Next, we examined whether formoterol modulates mTOR
signaling in human PAVSM cells by assessing mTORC1-
specific ribosomal protein S6 and mTORC2-specific S473-
Akt phosphorylation. Consistent with our published data
[20,25], serum-deprived human PAVSM cells had modest
S6 phosphorylation levels that were markedly increased
by thrombin and PDGF (Figure 5A). In contrast, PDGF,
but not thrombin, promoted S473-Akt phosphorylation
(Figure 5A) suggesting that both PDGF and thrombin acti-
vate mTORC1 signaling in human PAVSM cells while
only PDGF increases mTORC2 activity. As we reported
previously [25], exposure to chronic hypoxia led to a
marked increase in mTORC1-dependent P-S6K1 and P-S6
and mTORC2-dependent P-S473-Akt (Figure 5B) demon-
strating that chronic hypoxia activates both mTORC1 and
mTORC2 pathways in human PAVSM cells. Interestingly,
racemic formoterol and both (R,R) and (S,S) formoterol
enantiomers had no effect on basal, PDGF- and thrombin-
induced S6 phosphorylation either under normoxia or
chronic hypoxia (Figure 5C). PDGF-induced S473-Akt
phosphorylation was also comparable in diluent-, (R,R)-,
(S,S)-, and racemic formoterol-treated cells (Figure 5D).
Collectively, these data demonstrate that formoterol has
little effect on mTORC1 and mTORC2 signaling pathways
in human PAVSM cells.Discussion
PH is a progressive disease with poor prognosis, the patho-
logical manifestations of which include vasoconstriction
and pulmonary vascular remodeling [5,45]. PH may be fa-
milial, idiopathic, or associated with other diseases. Notably,
patients with COPD-associated PH have higher morbidity
and reduced survival compared to other COPD patients
[3,4]. Pulmonary vascular remodeling in PH is associated
with marked medial thickening of small muscular PAs due,
at least in part, to increased proliferation of PAVSM
cells. PAVSM cell proliferation in COPD-associated PH
is caused by multiple factors including persistent hy-
poxia and increased production of growth factors and
pro-inflammatory cytokines [2,31,46]. Our study demon-
strates that β2AR agonist formoterol inhibits proliferation of
PAVSM cells induced by thrombin and chronic hypoxia, but
not PDGF. Anti-proliferative activity of formoterol requires
binding with β2AR, and (R,R) enantiomer of formoterol
shows improved anti-growth effects compared to racemic
and (S,S) formoterol. We also report that formoterol inhibits
basal and thrombin-induced activation of ERK1/2, but has
no effect on mTOR signaling in human PAVSM cells.
Deregulated PAVSM cell proliferation is one of the
major pathological components of pulmonary vascular re-
modeling in PH. The long-term β2AR agonist formoterol,
which is currently in use as bronchodilator in COPD,
shows anti-proliferative activities in human airway smooth
muscle cells and bronchus fibroblasts [9,14]. In the present
study, we explored effects of formoterol on human
PAVSM cell proliferation caused by different stimuli
involved in PH pathogenesis [2,31,47] and found that the
growth-inhibitory potency of formoterol highly depends
on extracellular stimuli. Thus, formoterol and, especially,
its (R,R) enantiomer, inhibited proliferation of non-
stimulated PAVSM cells under chronic hypoxia, decreased
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Figure 4 Differential effects of formoterol on basal, thrombin- and PDGF-induced ERK1/2 phosphorylation in human PAVSM cells. A:
(R,R) and racemic, but not (S,S) formoterol inhibit ERK1/2 phosphorylation in human PAVSM cells. Cells serum-deprived for 48 h were treated with
10 μM (R,R), (S,S), racemic formoterol or diluent for 30 min followed by immunoblot analysis with anti-phospho ERK1/2 and anti-total ERK1/2
antibodies. Top panel: Images are representative of three independent experiments. Bottom panel: Statistical analysis of three separate
experiments, n = 3 for each experimental condition. Data represent mean values ± SE by ANOVA (Bonferroni-Dunn). Phospho-ERK/total ERK ratio
for diluent-treated cells was taken as one fold. B: Cells serum-deprived for 48 h were treated with 1 U/ml thrombin, 10 ng/ml PDGF, or diluent
for 30 min followed by immunoblot analysis with anti-phospho ERK1/2 and anti-total ERK1/2 antibodies. Top panel: Representative images from
three independent experiments. Bottom panel: Statistical analysis of three independent experiments; n = 3 for each experimental condition. Data
are mean values ± SE by ANOVA (Bonferroni-Dunn). Phospho-ERK/total ERK ratio for diluent-treated cells was taken as one fold. C, D: (R,R)
formoterol inhibits thrombin-, but not PDGF-induced ERK1/2 phosphorylation in human PAVSM cells. Cells were serum-deprived for 48 h,
incubated for 30 min with 10 μM (R,R), (S,S), or racemic formoterol in the presence or absence of 10 ng/ml PDGF, and then immunoblot analysis
with anti-phospho-ERK1/2 and anti-total ERK1/2 antibodies was performed. C: Representative images. D: Statistical analysis of three separate
experiments. Data are mean ± SE by ANOVA (Bonferroni-Dunn). Phospho/total ERK ratio for diluent-treated cells was taken as one fold.
*p < 0.05 for diluent vs. (R,R) formoterol; **p < 0.01 for diluent vs. thrombin; ***p < 0.01 for thrombin vs. thrombin + (R,R) formoterol.
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Figure 5 Formoterol does not affect mTORC1 and mTORC2 activation by chronic hypoxia, thrombin and PDGF. A: Human PAVSM cells
serum-deprived for 48 h were treated with 1 U/ml thrombin (thr), 10 ng/ml PDGF, or diluent (dil) for 30 min, and then immunoblot analysis with
anti-phospho S6, anti-total S6, anti-phospho S473-Akt, and anti-total Akt was performed. Images are representative of three independent
experiments. B: Chronic hypoxia promotes S6, S6K1, and S473-Akt phosphorylation in human PAVSM cells. Human PAVSM cells serum-deprived
for 48 h maintained under chronic hypoxia (hyp) or normoxia (norm) were subjected to immunoblot analysis with specific antibodies to detect
indicated proteins. Images are representative of three independent experiments. C, D: Formoterol has no effect on S6 and S473-Akt
phosphorylation. C: Serum-deprived cells maintained under hypoxia or normoxia were incubated for 30 min with 10 μM (R,R)-, (S,S), or racemic
formoterol, treated with different concentrations of thrombin and PDGF, or diluent, and then immunoblot analysis with anti-phospho-S6 and
anti-total S6 antibodies was performed. Representative images (top) and statistical analysis (bottom) of three independent experiments. Data
represent P/total S6 ratio (n = 3 for each experimental condition). P/total S6 ratio for diluent-treated normoxia-exposed cells was taken as one
fold). Data are means ± SE by ANOVA (Bonferroni-Dunn). *p < 0.001 for thrombin vs. diluent, thrombin + (R,R), (S,S) and racemic formoterol vs.
(R,R), (S,S) and racemic formoterol, respectively. D: Immunoblot analysis of serum-deprived normoxia-maintained cells treated as described above
was performed to detect P-S473-Akt and total Akt levels. Representative images (top) and data analysis (bottom) from three separate
experiments. Data represent P-S473/total Akt ratio (n = 3 for each experimental condition) normalized by P/total Akt for diluent-treated cells
(taken as one fold). Data are means ± SE by ANOVA (Bonferroni-Dunn). *p < 0.001 for PDGF vs. diluent, PDGF + (R,R) formoterol vs. (R,R)
formoterol, PDGF + (S,S) formoterol vs. (S,S) formoterol, and PDGF + racemic formoterol vs. racemic formoterol.
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fect on PDGF-dependent PAVSM cell growth.
The mechanisms of β2AR-dependent regulation of cell
proliferation are relatively unexplored and appear to be
highly cell type-specific. β2AR-induced PKA activation,
while inhibiting proliferation in the majority of cell types
including vascular smooth muscle cells [8-11,48,49] stimu-
lates proliferation of human uveal melanoma cells [50]
and cardiomyocyte hypertrophy [51]. Activation of β2AR-
cAMP signaling also up-regulates Epac1, the predominant
Epac isoform in VSM cells [7]. Epac1 synergizes with PKA
in inhibiting VSM cell proliferation [7], but increases
DNA synthesis in macrophages and prostate cancer cells
[52,53]. Our data show that formoterol-dependent inhib-
ition of human PAVSM cells requires its binding with
β2AR. Accordingly, (R,R) formoterol, which has much
higher receptor affinity and greater potency to induce
β2AR-Gs-dependent cAMP production and PKA acti-
vation compared to (S,S) formoterol [8,54], demonstrates
greater anti-proliferative effects than formoterol racemate
while (S,S) formoterol has modest effects on PAVSM
cell proliferation.
Emerging evidence shows that, in addition to classical
Gs-cAMP pathway, β2AR may interact with Gi proteins
that, in contrast to Gs, leads to reduction of cAMP levels
and inhibition of PKA-dependent signaling [55]. Currently,
no evidence exists about involvement of Gi in PAVSM cell
proliferation and pulmonary vascular remodeling in PH. In
contrast, Gs-dependent activation of cAMP-PKA signaling
is well documented in human ASM and PAVSM cells upon
formoterol treatment and is required for bronchodilatory
and vasodilatory effects of formoterol on COPD patients
and for inhibition of SM cell proliferation [7-11,56]. Gi
overexpression, however, has been reported in heart and
aorta of spontaneously hypertensive rats; and Gi suppres-
sion with pertussis toxin attenuated development of high
blood pressure in this model [55,57-59] suggesting differ-
ential mechanisms of β2AR signaling in heart vs. pulmon-
ary vasculature.
The signaling pathways underlying formoterol-dependent
inhibition of cell proliferation are not well evaluated. We
and others previously demonstrated that thrombin pro-
motes human PAVSM cell proliferation via ERK1/2 signal-
ing while PDGF acts via activation of two major pro-
proliferative pathways, PI3K-mTOR and MEK-ERK1/2
[60]. In the majority of cells, including VSM, cAMP-
dependent activation of PKA and Epac inhibits ERK1/2
signaling via modulating activities of small GTPases Raf-1
and Rap-1 downstream of Ras [15,61,62] clearly demon-
strating functional cross-talk between ERK1/2 and β2AR-
cAMP cascades.
Interestingly, we found that formoterol markedly inhi-
bits thrombin-, but not PDGF-induced ERK1/2 phos-
phorylation. A possible explanation is that PDGF, inaddition to ERK1/2, also promotes strong up-regulation
of PI3K signaling [20,25], and we found that PI3K is in-
sensitive to formoterol. PI3K stimulates ERK1/2 activa-
tion via Raf-1 and Rap-1 in a Ras-independent manner
[63,64] and can counter-balance formoterol-β2AR-
cAMP-dependent ERK1/2 inhibition. Indeed, our data
show that formoterol markedly inhibits ERK1/2 phos-
phorylation in chronic hypoxia-exposed PAVSM cells,
in which mTOR activation and proliferation occur in a
PI3K-independent manner [25].
Chronic hypoxia-induced proliferation of PAVSM cells
requires expression of hypoxia-inducible factor 1 α (HIF1α),
which plays a critical role in PAVSM remodeling in
human and experimental PH [31,65]. Notably, ERK1/2 up-
regulates HIF1α transcriptional activity via direct phosphor-
ylation that promotes HIF1α nuclear translocation or via
regulating binding of HIF1α with its major co-activator
p300/cAMP response element-binding protein (CBP) [66-
69]. Thus, formoterol may inhibit chronic hypoxia-induced
PAVSM cell proliferation via down-regulation of ERK1/2-
dependent HIF1α transcriptional activity.
Although much less is known about the regulation of
the mTOR signaling pathway by cAMP/PKA, it is shown
that cAMP elevation inhibits mTORC1/S6K1 in T lym-
phocytes [70], but not in CCL39 fibroblasts [71] suggest-
ing that effects of cAMP/PKA on mTOR activation are
cell type-specific. Our data show that formoterol has no
effect on activation of mTORC1 and mTORC2 signaling
pathways caused by either PDGF or chronic hypoxia.
These data indicate that mitogen- and chronic hypoxia-
induced mTOR activation in human PAVSM cells is
β2AR-independent.
Taken together, our study demonstrates that formoterol
inhibits basal, chronic hypoxia- and thrombin-, but not
PDGF-induced human PAVSM cell proliferation poten-
tially via β2AR-dependent inhibition of ERK1/2 signaling
pathway; and that anti-proliferative activity of formoterol
is provided predominantly by its (R,R) enantiomer. This
data suggests that (R,R) formoterol, while having a limited
effect as a single agent, may be considered as a potential
adjuvant therapy for COPD-associated PH.
Conclusions
Collectively, our data demonstrate that the β2AR agonist
formoterol inhibits basal, thrombin-, and chronic hypoxia-
induced ERK1/2 activation and proliferation of human
PAVSM cells, but has little effect on PDGF-induced
ERK1/2 activation, proliferation and mTOR signaling. We
also show that formoterol acts predominantly through its
(R,R) enantiomer and that anti-proliferative effects of
formoterol require β2AR binding. These data suggest that
(R,R) formoterol inhibits human PAVSM cell proliferation
in certain conditions and may be considered as a potential
adjuvant therapy for COPD-associated PH.
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